Welcome to our dedicated page for CERUS SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
NACHTSHEIM JAMI K reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Jami K. Nachtsheim received an equity grant of 60,000 restricted stock units (RSUs). These RSUs were awarded at no cash cost per unit and increase her direct holdings to 268,362 shares of common stock.
Each RSU represents a contingent right to receive one share of Cerus common stock. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as she continues serving the company through that vesting date.
CERUS CORP Chief Operating Officer Vivek K. Jayaraman sold shares in an open-market transaction. On May 29, 2026, he sold 16,667 shares of Cerus common stock at $3.00 per share in a sale reported as an open-market transaction.
The filing states that this transaction was executed pursuant to a Rule 10b5-1 trading plan, meaning it was pre-arranged rather than timed discretionarily. Following the sale, Jayaraman directly owned 1,656,707 shares of Cerus common stock.
Witney Frank reported acquisition or exercise transactions in this Form 4 filing.
CERUS CORP director Frank Witney reported an equity grant of 60,000 shares of Common Stock in the form of restricted stock units (RSUs). The RSUs were granted under Cerus’s 2024 Equity Incentive Plan, with each RSU representing a contingent right to receive one share of common stock.
The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of stockholders, as long as Witney remains in continuous service with Cerus through that vesting date. Following this grant, he directly holds 340,059 shares of common stock.
Cerus Corp director Gregory Dean A. reported receiving 60,000 shares of common stock in the form of restricted stock units (RSUs) granted under the company’s 2024 Equity Incentive Plan. Each RSU converts into one share and vests on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, as long as he continues serving the company. After this award, he directly holds 146,725 shares of Cerus common stock.
Shan Hua reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp director Shan Hua received a grant of 60,000 restricted stock units (RSUs) of common stock under the company’s 2024 Equity Incentive Plan. Each RSU represents one share of common stock. The RSUs vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, assuming continuous service. Following this award, Shan Hua holds 192,386 shares of common stock.
Issuer reported multiple sales of restricted common stock by an affiliate via Form 144. The submission lists individual transactions dated 05/01/2026, 03/13/2026 and 03/06/2026 showing sales of restricted Common stock with gross proceeds recorded for each trade.
CERUS CORP Chief Operating Officer Vivek K. Jayaraman reported an open-market sale of company stock. On May 1, 2026, he sold 16,667 shares of Cerus common stock at $3.00 per share. After this transaction, he directly holds 1,673,374 common shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was carried out under a pre-arranged instruction rather than as a discretionary trade.
CERS (Form 144): The filing reports sales of restricted common stock by Richard J. Benjamin in multiple transactions during March 2026. The largest disclosed sale was 101,740 shares on 03/13/2026. Other reported disposals occurred on 03/09/2026 (40,426 shares), 03/06/2026 (24,235 shares) and 03/05/2026 (61,233 shares), with dollar amounts shown for each trade.
Company CERS reported proposed and recent sales of restricted common stock by an affiliate via a Form 144 notice. The filing lists restricted shares issuable on 03/12/2019 (7,355 shares) and 03/12/2021 (9,312 shares), and discloses recent dispositions of 165,200 shares on 03/13/2026 and 34,094 shares on 03/06/2026 with reported transaction values.
Cerus Corporation reported improved Q1 2026 results, with revenue growing and losses narrowing. Product revenue reached $53.7 million for the three months ended March 31, 2026, up from $43.2 million a year earlier, while government contract revenue was $6.2 million versus $5.6 million.
Loss from operations narrowed to $0.4 million, compared with $5.9 million in the prior-year quarter. Net loss attributable to Cerus was $1.6 million, or $0.01 per share, better than the $7.7 million net loss and $0.04 loss per share a year ago.
Cerus ended the quarter with $27.9 million in cash and cash equivalents, $52.6 million in short-term investments and $0.6 million of restricted cash. Debt totaled $84.9 million, including $52.4 million classified as current. Operating activities used $3.0 million of cash, while investing activities provided $9.9 million mainly from investment maturities.